At AMP 2024, interventional radiologist Bret Wiechmann, MD, discussed his presentation on the OEIS Registry, which details outcomes within outpatient interventional suites to promote quality and identify benchmarks for best practices.
At AMP 2024, interventional radiologist Bret Wiechmann, MD, discussed his presentation on the OEIS Registry, which details outcomes within outpatient interventional suites to promote quality and identify benchmarks for best practices.
Vascular Disease Management recently spoke with interventional cardiologist Andrey Espinoza, MD, about this office-based lab (OBL) in Flemington, New Jersey.
Vascular Disease Management recently spoke with interventional cardiologist Andrey Espinoza, MD, about this office-based lab (OBL) in Flemington, New Jersey.
Laiq Raja, MD, FACC, FSCAI, from El Paso Cardiology Associates in El Paso, Texas, presented on the effective management of complex CLI)patients with wounds in an outpatient program.
Laiq Raja, MD, FACC, FSCAI, from El Paso Cardiology Associates in El Paso, Texas, presented on the effective management of complex CLI)patients with wounds in an outpatient program.
As part of an Early Career Session at ISET 2024, Michelle Maneevese, MD, presented “Starting an OBL from Scratch,” an overview of how she opened her office-based lab (OBL), and gave advice for those thinking of starting their own OBL.
As part of an Early Career Session at ISET 2024, Michelle Maneevese, MD, presented “Starting an OBL from Scratch,” an overview of how she opened her office-based lab (OBL), and gave advice for those thinking of starting their own OBL.
Careful selection of which cases not to take is an effective way of avoiding complications in an OBL. Determining what cases to avoid is largely dependent on 4 major variables: the physician, the patient, the procedure, and the OBL itself.
Careful selection of which cases not to take is an effective way of avoiding complications in an OBL. Determining what cases to avoid is largely dependent on 4 major variables: the physician, the patient, the procedure, and the OBL itself.
VentiV Scientific announced the FDA clearance of VentiV Mechanical Thrombectomy system to remove blood clots from the peripheral vasculature including the new VentiV Pulse platform.
VentiV Scientific announced the FDA clearance of VentiV Mechanical Thrombectomy system to remove blood clots from the peripheral vasculature including the new VentiV Pulse platform.
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
Medtronic has released results from the two-year point of a clinical trial comparing its Evolut to Edwards Lifesciences’ SAPIEN. The results revealed that the Evolut showed superior performance to the SAPIEN. Specifically, the Evolut showed...
Medtronic has released results from the two-year point of a clinical trial comparing its Evolut to Edwards Lifesciences’ SAPIEN. The results revealed that the Evolut showed superior performance to the SAPIEN. Specifically, the Evolut showed...
BEDFORD, Mass., March 11, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration...
BEDFORD, Mass., March 11, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration...
“Resistant hypertension is a serious public health challenge. Patients whose hypertension remains in poor control despite receiving optimal care, including multiple medications, are at greater risk of cardiovascular morbidity and mortality,”...
“Resistant hypertension is a serious public health challenge. Patients whose hypertension remains in poor control despite receiving optimal care, including multiple medications, are at greater risk of cardiovascular morbidity and mortality,”...
Reflow Medical, Inc., a developer of innovative medical devices for complex cardiovascular disease, has announced the opening of its European subsidiary in Landsberg am Lech, Germany.
Reflow Medical, Inc., a developer of innovative medical devices for complex cardiovascular disease, has announced the opening of its European subsidiary in Landsberg am Lech, Germany.
A survey conducted by the Society for Cardiovascular Angiography and Interventions (SCAI) highlights ongoing radiation and orthopedic hazards faced by interventional cardiologists and cardiac catheterization laboratory (“cath lab” or CCL)...
A survey conducted by the Society for Cardiovascular Angiography and Interventions (SCAI) highlights ongoing radiation and orthopedic hazards faced by interventional cardiologists and cardiac catheterization laboratory (“cath lab” or CCL)...
Now available in the U.S., the Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter safely modifies and crosses occlusive or extremely narrowed calcific peripheral artery disease.
Now available in the U.S., the Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter safely modifies and crosses occlusive or extremely narrowed calcific peripheral artery disease.
Genentech announced that the U.S. FDA has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Genentech announced that the U.S. FDA has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
